[go: up one dir, main page]

BR0317834A - Pyrimidin-4,6-dicarboxylic acid diacids as selective 13 mmp inhibitors - Google Patents

Pyrimidin-4,6-dicarboxylic acid diacids as selective 13 mmp inhibitors

Info

Publication number
BR0317834A
BR0317834A BR0317834-0A BR0317834A BR0317834A BR 0317834 A BR0317834 A BR 0317834A BR 0317834 A BR0317834 A BR 0317834A BR 0317834 A BR0317834 A BR 0317834A
Authority
BR
Brazil
Prior art keywords
pyrimidin
selective
dicarboxylic acid
mmp inhibitors
mmp
Prior art date
Application number
BR0317834-0A
Other languages
Portuguese (pt)
Inventor
Otmar Klingler
Reinhard Kirsch
Joerg Habermann
Klaus-Ulrich Weithmann
Christian Engel
Bernard Pirard
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0317834A publication Critical patent/BR0317834A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DIAMIDAS DE áCIDO PIRIMIDIN-4,6-DICARBOXìLICO COMO INIBIDORES MMP 13 SELETIVOS". A presente invenção refere-se à aplicação da fórmula (I) na qual R1-R7 têm os significados indicados nas reivindicações, bem como sua aplicação para a inibição seletiva da colagenase (MMP 13). As diamidas de ácido pirimidin-4,6-dicarboxílico podem ser aplicadas, por conseguinte, para o tratamento de doenças articulares degenerativas."PYRIMIDIN-4,6-DICARBOXYLIC ACID DIAMIDES AS SELECTIVE MMP 13 INHIBITORS". The present invention relates to the application of formula (I) wherein R1-R7 have the meanings indicated in the claims as well as its application to selective collagenase inhibition (MMP 13). Pyrimidin-4,6-dicarboxylic acid diamides may therefore be applied for the treatment of degenerative joint diseases.

BR0317834-0A 2003-01-03 2003-12-19 Pyrimidin-4,6-dicarboxylic acid diacids as selective 13 mmp inhibitors BR0317834A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10300017A DE10300017A1 (en) 2003-01-03 2003-01-03 Selective MMP 13 inhibitors
PCT/EP2003/014612 WO2004060883A1 (en) 2003-01-03 2003-12-19 Pyrimidine-4,6-dicarboxylic acid diamides for use as selective mmp 13 inhibitors

Publications (1)

Publication Number Publication Date
BR0317834A true BR0317834A (en) 2005-11-29

Family

ID=32519591

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317834-0A BR0317834A (en) 2003-01-03 2003-12-19 Pyrimidin-4,6-dicarboxylic acid diacids as selective 13 mmp inhibitors

Country Status (11)

Country Link
EP (1) EP1587803A1 (en)
JP (1) JP2006515595A (en)
AR (1) AR042687A1 (en)
AU (1) AU2003293951A1 (en)
BR (1) BR0317834A (en)
CA (1) CA2512183A1 (en)
DE (1) DE10300017A1 (en)
MX (1) MXPA05006401A (en)
PE (1) PE20040916A1 (en)
TW (1) TW200505906A (en)
WO (1) WO2004060883A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
US20070155737A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
JP2009522295A (en) * 2005-12-30 2009-06-11 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド Substituted bis-amide metalloprotease inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008063669A1 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic matrix metalloprotease inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
JP2013525371A (en) 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド Method for producing cycloalkylcarboxamide-indole compound
HUE039062T2 (en) 2014-04-15 2018-12-28 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931432A1 (en) * 1989-09-21 1991-04-04 Hoechst Ag PYRIMIDIN-4,6-DICARBONSAEUREDIAMIDE, METHOD FOR THE PRODUCTION AND USE THEREOF AND MEDICINAL PRODUCTS BASED ON THESE COMPOUNDS
BR0207209A (en) * 2001-02-14 2004-01-27 Warner Lambert Co Pyrimidine Matrix Metalloproteinase Inhibitors
DE10160357A1 (en) * 2001-12-08 2003-06-18 Aventis Pharma Gmbh Use of pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides for the selective inhibition of collagenases

Also Published As

Publication number Publication date
AU2003293951A1 (en) 2004-07-29
EP1587803A1 (en) 2005-10-26
WO2004060883A1 (en) 2004-07-22
CA2512183A1 (en) 2004-07-22
TW200505906A (en) 2005-02-16
DE10300017A1 (en) 2004-07-15
JP2006515595A (en) 2006-06-01
AR042687A1 (en) 2005-06-29
MXPA05006401A (en) 2005-08-19
PE20040916A1 (en) 2005-01-25

Similar Documents

Publication Publication Date Title
BR0209774A (en) Cdk inhibitor pyrimidines, their preparation and application as a medicament
BR0316680A (en) Chk, pdk and akt inhibitor pyrimidines, their production and use as pharmaceutical agents
BRPI0415683A (en) norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
BR0307564A (en) Nicotinamide derivatives useful as pde4 inhibitors
BRPI0513864A (en) compounds, process for their manufacture, pharmaceutical compositions comprising them, their use and method for the treatment and / or prophylaxis of diseases
BR0309556A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
BR0114917A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
BRPI0516842A (en) compounds, process for their manufacture, pharmaceutical compositions comprising them, method for the therapeutic and / or prophylactic treatment of diseases that are modulated by lxr alpha and / or lxr beta agonists and use of such compounds
BR0317872A (en) Anti-Inflammatory Drugs
BR0207726A (en) Pharmaceutical Salts
BRPI0515931A (en) compounds, process for their preparation, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases and use of such compounds
BRPI0112986B8 (en) azabicyclic compounds, process for their preparation, as well as pharmaceutical compositions comprising said compounds
BR0314379A (en) Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
BR0314393A (en) Heterocyclic Substituted Piperazines for the Treatment of Schizophrenia
BRPI0408347B8 (en) pyrimidine derivatives, their use, and pharmaceutical composition and combination
BR0207883A (en) Anticholenergic and pde-iv inhibitor drug compositions
BR0209957A (en) Compound, process for preparing a compound, pharmaceutical composition comprising a compound, use of such compound and process for the treatment and prophylaxis of arthritis, diabetes, eating disorders and obesity
BR0112538A (en) Stable salts of o-acetylsalicylic acid with basic amino acids
BR0316606A (en) Aminoindazole derivatives and their use as kinase inhibitors
BRPI0409627A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
BR0206501A (en) Cruzipain and other cysteine protease inhibitors
PA8559401A1 (en) SUCCINIC ACID SALTS OF 5,7,14-TRIAZATETRACICLO (10.3.1.0 2,11.0 4, 9) -HEXADECA-2 (11), 3,5,7,9-PENTAENO AND PHARMACEUTICAL COMPOSITIONS OF THE SAME.
CR8926A (en) TIAZOLO-NAFTILO ACIDS
BRPI0517435A (en) triazoles useful as protein kinase inhibitors
BRPI0414948A (en) pyrazolo-e-imidazo pyrimidine derivatives

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.